Feb 25th 2013 - Edison Investment Research today published a report on quickview entitled "US Hopes Re-awaken". In summary, the report says:
The FDA’s acceptance of the Oralair filing has re-awakened hopes that Stallergenes is still in the race to launch the first allergy immunotherapy tablet in the US. Progress with the tablets in EU, US and Japan in various indications is likely to be a key value driver for the shares, with first potential US Oralair launch in Q114, and continuation of the clinical development plan of the dust mite Actair tablet during 2013.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »